Acarix AB

Acarix AB maintains a strong liquidity position with a current ratio of 7.5 and holds SEK 63.9 million in cash and equivalents, representing 66.7% of total assets. The company is entirely equity-funded, with no long-term debt, and a debt-to-equity ratio of 0.0. However, negative operating cash flow of SEK -18.4 million and free cash flow of SEK -14.4 million indicate ongoing cash burn, which could pressure liquidity if not offset by revenue growth or financing. Profitability metrics are sharply negative, with a return on equity of -17.63% and return on assets of -15.58%, both well below the industry median for medical equipment firms. Gross profit of SEK 1.41 million on revenue of SEK 1.55 million suggests high cost of goods sold, while operating and net losses of SEK -14.93 million reflect significant R&D and SG&A expenses. The company operates as a single business segment with no disclosed geographic diversification. All revenue is generated from undisclosed markets, creating concentration risk. No material revenue is attributed to specific regions or customers, and the company does not report segment or geographic breakdowns in its latest filings. Acarix is in a high-growth phase, with analysts forecasting revenue to increase from SEK 7.36 million to SEK 20 million in the current fiscal year. However, the company is not yet profitable, with EBIT estimates at -SEK 35 million. The mean price target of SEK 0.40 implies a 56.6% upside from the current market price of SEK 0.2555, but this is contingent on achieving revenue and margin expansion. Risk factors include liquidity pressure from negative cash flows and the absence of long-term debt capacity. The company has no immediate dilution risk, with basic and diluted shares outstanding aligned at 1.16 billion. No recent equity issuances or shelf registration events have been reported, and the risk assessment flags no filing-based dilution concerns. Recent events include the publication of Q4 2023 financial results, which showed a revenue increase from SEK 7.36 million to SEK 15.52 million year-over-year. The company also announced a partnership with a European distributor to expand its market reach. No material regulatory or geopolitical risks were disclosed in the latest filings.